Prognostic Value of the Six-Minute Walk in Advanced Non-small Cell Lung Cancer

Kasymjanova, G.; Correa, José A.; Kreisman, Harvey; Dajczman, Esther; Pepe, C.; Dobson, S.; Lajeunesse, L.; Sharma, Rajesh; Small, David

doi:10.1097/jto.0b013e31819e77e8

Cited by 131 publications

(106 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognostic value of the 6MWT in patients with NSCLC has been investigated, and the results have shown that the 6MWD decreases after the second cycle of chemotherapy and that a 6MWD ≥ 400 m can be a positive prognostic factor for these patients. (27) A recent study investigating patients with NSCLC who were evaluated before and one month after chemotherapy reported that there was no significant reduction in the 6MWD after the treatment, (26) a finding that was similar to those of the present study, in which there was no reduction in the 6MWD after chemotherapy or at six months after the start of treatment.…”

Section: Discussionsupporting

confidence: 88%

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia

et al. 2010

View full text Add to dashboard Cite

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia Luciana Machado, Ivete Alonso Bredda Saad, Helen Naemi Honma, André Moreno Morcillo, Lair Zambon Abstract Objective: To evaluate the effect of chemotherapy on the physical condition of patients with advanced lung cancer. Methods: We evaluated 50 patients with non-small cell lung cancer (in stages IIIB and IV) and Eastern Cooperative Oncology Group (ECOG) performance status scale scores between zero and two. All patients underwent chemotherapy using paclitaxel and platinum derivatives and were evaluated at three time points (prechemotherapy, postchemotherapy and six months after starting the treatment), at which the ECOG scale, the body mass index (BMI) and the six-minute walk distance (6MWD) were assessed. Results: Of the 50 patients included in the study, 14 died, 5 were excluded due to the worsening of their performance status, and 31 completed the six-month follow-up. There was no statistically significant difference between the time points of assessment for BMI (prechemotherapy vs. postchemotherapy, p = 1.00; and prechemotherapy vs. six months later, p = 0.218) or for 6MWD. Performance status improved, and this was especially due to the increase in the number of asymptomatic patients after the six-month follow-up (p = 0.031). Conclusions: Chemotherapy had a beneficial effect on the performance status of the patients. No significant changes in BMI or 6MWD were found during the study period, which might suggest the maintenance of the physical condition of the patients. 2 ) and carboplatin (area under the curve/5 = 300-600 mg/m 2 ). The initial exclusion criteria were as follows: having previously undergone lung surgery; and presenting with brain metastasis. During the study period, patients who presented with an ECOG PS score > 2 were excluded, in accordance with the treatment protocol of our facility, where chemotherapy is not given to such patients. (7) Therefore, the only exclusion criterion adopted during the follow-up visits was presenting with an elevated ECOG PS scale score (> 2).All of the patients gave written informed consent. The study was approved by the local research ethics committee (ruling no. 209/2006).The patients were selected during medical visits to the Lung Cancer Outpatient Clinic of the State University at Campinas Hospital das Clínicas, located in the city of Campinas, Brazil.After the inclusion criteria had been applied, the patients were evaluated and data were collected.The evaluations and data collection were carried out at three time points: prechemotherapy; postchemotherapy (two weeks after the last cycle of chemotherapy); and six months after the start of treatment. The evaluation consisted of collecting personal data, determining PS, evaluating BMI, and administering the 6MWT.In order to determine the PS, we used the ECOG scale, which measures the overall functional performance of patients...

show abstract

Section: Discussionsupporting

confidence: 88%

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Cancer patients who are more physically able are less likely to have treatment resistant-disease 46 and to experience increased life expectancy [46][47][48] .…”

Section: 11mentioning

confidence: 99%

Exercise and Nutrition Interventions in Advanced Lung Cancer: A Systematic Review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In addition, we did not exclude patients with a significant delay between objective testing and initiation of chemotherapy. It is possible that the predictive value of baseline objective markers of physical health for chemotherapy toxicity could decline with time 43 . Although few toxicities occurred more than 3 months after chemotherapy initiation, standardizing the time for observation of toxicities (using, for example, 3 months) might be important in future studies examining the relationship between baseline objective testing and chemotherapy toxicity.…”

Section: Discussionmentioning

confidence: 99%

Pilot of Three Objective Markers of Physical Health and Chemotherapy Toxicity in Older Adults

et al. 2015

View full text Add to dashboard Cite

show abstract

Prognostic Value of the Six-Minute Walk in Advanced Non-small Cell Lung Cancer

Cited by 131 publications

References 24 publications

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia

Exercise and Nutrition Interventions in Advanced Lung Cancer: A Systematic Review

Pilot of Three Objective Markers of Physical Health and Chemotherapy Toxicity in Older Adults

Contact Info

Product

Resources

About